| Q2 2026 Preview: 6 FDA Decisions to Watch | HCPLive |
hcplive.com |
1 |
Apr 03, 2026 |
www.hcplive.com |
| [PDF] New Drug Therapy Approvals 2025 | FDA |
www.fda.gov |
1 |
— |
www.fda.gov |
| FDA Drug Approval Decisions Expected in August 2025 |
www.clinicalpainadvisor.com |
1 |
— |
www.clinicalpaina... |
| Phase 3 Clinical Trials With Primary Completion Dates in August 2025 |
www.fdatracker.com |
2 |
— |
www.fdatracker.com |
| Biotech FDA Catalyst Database | FDA Catalyst Calendar | Clinical ... |
biopharmiq-frontend.vercel.app |
1 |
— |
biopharmiq-fronte... |
| [PDF] FY 2025 PDUFA Performance Report - FDA |
www.fda.gov |
1 |
— |
www.fda.gov |
| All FDA Approval News and Press Releases from PR Newswire |
www.prnewswire.com |
1 |
— |
www.prnewswire.com |
| Regulatory News & FDA Approvals - Precision Medicine Online |
www.precisionmedicineonline.com |
4 |
— |
www.precisionmedi... |
| Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease |
ir.viridiantherapeutics.com |
3 |
Mar 30, 2026 |
ir.viridiantherap... |
| Regulatory tracker: Vertex secures broader FDA labels for cystic fibrosis meds Alyftrek, Trikafta | Fierce Pharma |
fiercepharma.com |
4 |
Apr 01, 2026 |
www.fiercepharma.com |
| FDA Approves First Once-Weekly Insulin for Type 2 Diabetes |
medscape.com |
1 |
Mar 30, 2026 |
www.medscape.com |
| FDA Approves First New Molecular Entity Under National Priority Voucher Program |
fda.gov |
1 |
Apr 01, 2026 |
www.fda.gov |
| Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis |
prnewswire.com |
1 |
Apr 03, 2026 |
www.prnewswire.com |
| FDA Action Update, March 2026: Lift on CRL, Expanded Approvals, and Priority Review |
neurologylive.com |
2 |
Apr 02, 2026 |
www.neurologylive.com |
| New FDA Drug Approvals for 2026 - Drugs.com |
drugs.com |
1 |
Apr 01, 2026 |
www.drugs.com |
| Capricor Therapeutics Provides Regulatory Update on Deramiocel ... |
www.capricor.com |
1 |
— |
www.capricor.com |
| FDA urges clinical trial sponsors to report the results of their studies - Fierce Biotech |
fiercebiotech.com |
1 |
Apr 13, 2026 |
www.fiercebiotech.com |
| Upcoming FDA Approvals: New Drugs and Therapies That May Be Approved in 2026 - GoodRx |
goodrx.com |
3 |
Apr 13, 2026 |
www.goodrx.com |
| 5 FDA Drug Approvals That Could Shape Biotech in 2026 - Intelacia |
intelacia.com |
1 |
Feb 13, 2026 |
www.intelacia.com |
| FDA-TRACK: Prescription Drug User Fee Act (PDUFA) Performance Reports |
fda.gov |
1 |
Apr 17, 2026 |
www.fda.gov |
| Capricor Therapeutics Announces Establishment of New PDUFA ... |
www.capricor.com |
1 |
— |
www.capricor.com |
| Priovant Announces FDA Acceptance and Priority Review of New ... |
investor.roivant.com |
1 |
— |
investor.roivant.com |
| Genentech's Fenebrutinib Shows Unprecedented Positive Phase III ... |
www.gene.com |
1 |
— |
www.gene.com |
| Vera Therapeutics Announces U.S. FDA Granted Priority Review to ... |
ir.veratx.com |
1 |
— |
ir.veratx.com |
| Phase III Clinical Trials - BioSpace |
www.biospace.com |
1 |
— |
www.biospace.com |
| Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met ... |
ir.genmab.com |
1 |
— |
ir.genmab.com |
| Phase 3 Clinical Trials With Primary Completion Dates in December ... |
www.fdatracker.com |
2 |
— |
www.fdatracker.com |
| FDA Drug Approval Decisions Expected in April 2026 |
www.gastroenterologyadvisor.com |
1 |
— |
www.gastroenterol... |
| Press Releases - Investors | Larimar Therapeutics, Inc. |
investors.larimartx.com |
1 |
— |
investors.larimartx.com |
| Rusfertide Demonstrates Promising Results in Phase 3 VERIFY Trial ... |
www.takeda.com |
1 |
— |
www.takeda.com |
| FDA Drug Approval Decisions Expected in November 2025 - MPR |
www.empr.com |
1 |
— |
www.empr.com |
| Vertex Announces Positive Week 36 Interim Analysis Results for ... |
news.vrtx.com |
1 |
— |
news.vrtx.com |
| FDA Decisions Expected: August 2025 - Prime Therapeutics - Portal |
www.primetherapeutics.com |
1 |
— |
www.primetherapeutics.com |
| Novel Drug Approvals for 2025 | FDA |
www.fda.gov |
1 |
— |
www.fda.gov |
| PDUFA Dates, FDA Approval Dates | BiopharmIQ - Catalyst Calendar |
biopharmiq.com |
2 |
Apr 23, 2026 |
app.bpiq.com |
| Tag: Phase 3 Trial - BiotechReality |
biotechreality.com |
3 |
Apr 16, 2026 |
www.biotechreality.com |
| 5 FDA Decisions for Primary Care to Know from March 2026 |
vertexaisearch.cloud.google.com |
3 |
Apr 01, 2026 |
www.patientcareonline.com |
| Vera Therapeutics Announces U.S. FDA Granted Priority Review to ... |
ir.veratx.com |
1 |
— |
ir.veratx.com |
| Aldeyra Therapeutics Announces PDUFA Extension of the New ... |
ir.aldeyra.com |
1 |
— |
ir.aldeyra.com |
| Mineralys Therapeutics Announces FDA Acceptance of NDA for ... |
www.biospace.com |
1 |
— |
www.biospace.com |
| UroGen Announces FDA Acceptance of its New Drug Application for ... |
investors.urogen.com |
1 |
— |
investors.urogen.com |
| Vertex Announces Progress in Povetacicept Development Program ... |
news.vrtx.com |
2 |
— |
news.vrtx.com |
| FDA Regulatory Highlights in Oncology: March 2026 |
vertexaisearch.cloud.google.com |
3 |
Mar 31, 2026 |
www.targetedonc.com |
| Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ... |
ir.corcept.com |
2 |
— |
ir.corcept.com |
| FDA Decisions Expected: April 2026 - Prime Therapeutics - Portal |
www.primetherapeutics.com |
1 |
Mar 17, 2026 |
www.primetherapeutics.com |
| Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting - Stock Titan |
stocktitan.net |
2 |
Apr 22, 2026 |
www.stocktitan.net |
| Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting |
globenewswire.com |
2 |
Apr 22, 2026 |
www.capricor.com |
| Clinical Data - BiotechReality |
biotechreality.com |
2 |
Apr 22, 2026 |
www.biotechreality.com |
| New Drugs and Therapies That May Be Approved in 2026 - GoodRx |
www.goodrx.com |
1 |
— |
www.goodrx.com |
| New Drugs and Therapies That May Be Approved in 2026 - GoodRx |
www.goodrx.com |
1 |
— |
www.goodrx.com |
| 2025 approvals: Biopharma delivered 55 new drugs, biologics |
www.fiercepharma.com |
1 |
— |
www.fiercepharma.com |
| FDA plans to require just a single clinical trial for new approvals |
www.statnews.com |
1 |
— |
www.statnews.com |
| FDA Piloting Real-Time Review of Clinical Trial Data From AstraZeneca, Amgen |
vertexaisearch.cloud.google.com |
1 |
Apr 29, 2026 |
www.clinicalresea... |
| FDA moves toward real-time review of clinical trial data | TechTarget |
vertexaisearch.cloud.google.com |
3 |
Apr 30, 2026 |
www.techtarget.com |
| FDA Decisions Expected: January 2026 - Prime Therapeutics - Portal |
vertexaisearch.cloud.google.com |
3 |
Jan 10, 2026 |
www.primetherapeutics.com |
| EDSA: FDA Agrees on Primary Endpoint for Phase 3 ARDS Drug ... |
finance.yahoo.com |
1 |
— |
finance.yahoo.com |
| FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board - Fierce Biotech |
fiercebiotech.com |
1 |
Apr 28, 2026 |
www.fiercebiotech.com |
| Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint ... |
markets.businessinsider.com |
1 |
— |
markets.businessi... |
| FDA Shifts Toward Single Trial Requirement for New Drug Approvals |
pharmaceuticalcommerce.com |
1 |
Feb 19, 2026 |
www.pharmaceutica... |
| FDA's Shift to One Pivotal Trial for Drug Approval: Strategic Implications for Sponsors |
appliedclinicaltrialsonline.com |
1 |
Feb 24, 2026 |
www.propharmagroup.com |
| 2026 Clinical Trial Outlook: Key Phase 3 Reports & FDA Filings for New Drugs - ChemDiv |
chemdiv.com |
2 |
Jan 17, 2026 |
www.chemdiv.com |
| 5 FDA drug approvals to watch in 2026 - PharmaVoice |
pharmavoice.com |
2 |
Jan 07, 2026 |
www.pharmavoice.com |
| Celcuity (CELC) posts positive Phase 3 gedatolisib data, eyes FDA sNDA and July 2026 PDUFA - Stock Titan |
stocktitan.com |
3 |
May 01, 2026 |
www.stocktitan.net |
| Celcuity Phase 3 trial hits primary PFS endpoint | CELC Stock News |
stocktitan.com |
1 |
May 01, 2026 |
www.stocktitan.net |
| Arvinas and Pfizer Announce FDA Approval of VEPPANU™ as First-Ever PROTAC for Advanced Breast Cancer Treatment | Quiver Quantitative |
quiverquant.com |
1 |
May 01, 2026 |
www.quiverquant.com |
| Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones - MSD |
msd.com |
4 |
Apr 30, 2026 |
www.msd.com |
| FDA Drug Approval Decisions Expected in March 2026 |
www.neurologyadvisor.com |
1 |
— |
www.neurologyadvisor.com |
| First PROTAC: Arvinas' Veppanu wins FDA nod in breast cancer | BioWorld |
vertexaisearch.cloud.google.com |
1 |
May 01, 2026 |
www.bioworld.com |
| FDA Recommends AstraZeneca's Truqap for Prostate Cancer - AllSci |
vertexaisearch.cloud.google.com |
1 |
May 01, 2026 |
allsci.com |
| [8-K] Vera Therapeutics, Inc. Reports Material Event - Stock Titan |
vertexaisearch.cloud.google.com |
2 |
May 07, 2026 |
www.stocktitan.net |
| Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease - Drugs.com |
Drugs.com |
3 |
May 06, 2026 |
www.drugs.com |
| Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement |
vertexaisearch.cloud.google.com |
3 |
May 04, 2026 |
seekingalpha.com |
| Summit's ivonescimab heads toward November FDA decision as HARMONi-3 interim PFS misses threshold - AllSci |
vertexaisearch.cloud.google.com |
2 |
May 01, 2026 |
allsci.com |
| FDA Launches Real-Time Clinical Trials Pilot with AstraZeneca and Amgen - HLTH |
hlth.com |
3 |
Apr 30, 2026 |
hlth.com |
| FDA marks progress in implementing real-time clinical trials |
pharmaceutical-technology.com |
3 |
May 04, 2026 |
www.europeanpharm... |
| FDA Issues Regulatory Update - New York County Dental Society |
nycds.org |
3 |
May 04, 2026 |
www.nycdentalsociety.org |
| Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones |
vertexaisearch.cloud.google.com |
3 |
Apr 30, 2026 |
www.merck.com |
| FDA News & Analysis - Panabee |
www.panabee.com |
1 |
— |
www.panabee.com |
| Phase 3 Clinical Trials With Primary Completion Dates in March 2024 |
www.fdatracker.com |
2 |
— |
www.fdatracker.com |
| Phase 3 Clinical Trials With Primary Completion Dates in June 2024 |
www.fdatracker.com |
2 |
— |
www.fdatracker.com |
| Phase 3 Clinical Trials With Primary Completion Dates in July 2024 |
www.fdatracker.com |
2 |
— |
www.fdatracker.com |
| New Drugs and Therapies That May Be Approved in 2026 - GoodRx |
www.goodrx.com |
1 |
— |
www.goodrx.com |
| Celcuity (CELC) posts positive Phase 3 gedatolisib data, eyes FDA sNDA and July 2026 PDUFA - Stock Titan |
stocktitan.net |
3 |
May 01, 2026 |
www.stocktitan.net |
| Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease |
vertexaisearch.cloud.google.com |
1 |
May 05, 2026 |
investors.viridia... |
| Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint ... |
ir.celcuity.com |
1 |
— |
ir.celcuity.com |
| Phase III Clinical Trials - BioSpace |
www.biospace.com |
3 |
May 08, 2026 |
www.biospace.com |
| Upcoming FDA Approvals: New Drugs and Therapies That May Be Approved in 2026 |
www.goodrx.com |
3 |
Apr 13, 2026 |
www.goodrx.com |
| FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board - Fierce Biotech |
www.fiercebiotech.com |
3 |
Apr 28, 2026 |
www.fiercebiotech.com |
| 2026 Clinical Trial Outlook: Key Phase 3 Reports & FDA Filings for New Drugs - ChemDiv |
chemdiv.com |
3 |
Jan 17, 2026 |
chemdiv.com |
| PDUFA - Drugs on deck: FDA approval action dates - Bioworld |
www.bioworld.com |
1 |
May 06, 2026 |
www.bioworld.com |
| FDA-TRACK: Prescription Drug User Fee Act (PDUFA) Performance Dashboards |
www.fda.gov |
1 |
Apr 17, 2026 |
www.fda.gov |
| Astrazeneca (AZN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat |
www.marketbeat.com |
2 |
May 09, 2026 |
www.marketbeat.com |
| Phase III Clinical Trials - BioSpace |
www.biospace.com |
3 |
May 06, 2026 |
www.biospace.com |
| Novel Drug Approvals for 2026 - FDA |
www.fda.gov |
5 |
May 01, 2026 |
www.fda.gov |
| FDA marks progress in implementing real-time clinical trials |
www.raps.org |
3 |
May 04, 2026 |
www.raps.org |
| Upcoming FDA Approvals: New Drugs and Therapies That May Be Approved in 2026 |
www.goodrx.com |
4 |
Apr 13, 2026 |
www.goodrx.com |
| argenx Announces U.S. FDA Approval Expanding VYVGART and |
GlobeNewswire |
1 |
May 08, 2026 |
www.globenewswire.com |
| FDA Launches Proof-of-Concept Real-Time Clinical Trials |
vertexaisearch.cloud.google.com |
1 |
Apr 29, 2026 |
www.appliedclinic... |
| News | Applied Clinical Trials Online |
Applied Clinical Trials Online |
3 |
May 11, 2026 |
www.appliedclinic... |
| Clinical Trial News & Results - Drugs.com |
Drugs.com |
3 |
May 12, 2026 |
www.drugs.com |
| Three 2026 FDA Decisions Testing Whether New Drugs Can Beat Imperfect Standards: Unicycive, Protagonist And Savara ($UNCY $PTGX $SVRA) - Merlintrader Trading Pub |
merlintrader.com |
3 |
May 09, 2026 |
www.merlintrader.com |
| Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease |
www.businesswire.com |
2 |
May 05, 2026 |
www.businesswire.com |
| Phase III Clinical Trials |
www.biospace.com |
3 |
May 14, 2026 |
www.biospace.com |
| Phase 3 Trial Finds Moderna's mRNA-1010 Influenza Vaccine Outperformed Standard-Dose Vaccines in Adults Aged 50 Years and Older |
www.appliedclinicaltrialsonline.com |
1 |
May 11, 2026 |
www.appliedclinic... |
| TransCelerate and FDA Advance Work on Streamlined Safety Data Collection for Pragmatic Clinical Trials |
www.appliedclinicaltrialsonline.com |
1 |
May 08, 2026 |
www.appliedclinic... |
| Incyte Announces Week 24 Results from TRuE-AD4 Phase III Trial of Opzelura |
www.appliedclinicaltrialsonline.com |
1 |
May 07, 2026 |
www.appliedclinic... |
| First Patient Dosed with Azenosertib in Aspenova Phase III Trial for Treatment of Ovarian Cancer |
www.appliedclinicaltrialsonline.com |
1 |
May 14, 2026 |
www.appliedclinic... |
| Guselkumab Phase 3 Data Show Higher Fistula Remission in Perianal Crohn Disease |
www.appliedclinicaltrialsonline.com |
1 |
May 14, 2026 |
www.appliedclinic... |
| Clinical Trial News & Results - Drugs.com |
www.drugs.com |
2 |
May 12, 2026 |
www.drugs.com |
| Fierce Biotech News & Reports |
www.fiercebiotech.com |
2 |
May 13, 2026 |
www.fiercebiotech.com |
| PDUFA Dates, FDA Approval Dates | BiopharmIQ - Catalyst Calendar |
www.biopharmcatalyst.com |
3 |
May 14, 2026 |
www.biopharmcatalyst.com |
| 2026 Clinical Trial Outlook: Key Phase 3 Reports & FDA Filings for New Drugs - ChemDiv |
www.chemdiv.com |
2 |
Jan 17, 2026 |
www.chemdiv.com |
| FDA marks progress in implementing real-time clinical trials |
www.europeanpharmaceuticalreview.com |
1 |
May 04, 2026 |
www.europeanpharm... |
| Three 2026 FDA Decisions Testing Whether New Drugs Can Beat Imperfect Standards: Unicycive, Protagonist And Savara ($UNCY $PTGX $SVRA) - Merlintrader Trading Pub |
www.merlintradertradingpub.com |
2 |
May 09, 2026 |
www.merlintradert... |
| Novel Drug Approvals for 2026 - FDA |
www.fda.gov |
6 |
May 13, 2026 |
www.fda.gov |
| TransCelerate and FDA Advance Collaboration on Streamlined Safety Data Collection to Accelerate Inclusion of Pragmatic Elements in Clinical Trials - PR Newswire |
prnewswire.com |
1 |
May 05, 2026 |
www.prnewswire.com |
| FDA Announces Major Steps to Implement Real-Time Clinical Trials |
vertexaisearch.cloud.google.com |
3 |
Apr 28, 2026 |
www.fda.gov |
| 4 pending FDA approvals payers, PBMs, and market access teams should be preparing for now - Milliman |
vertexaisearch.cloud.google.com |
2 |
May 13, 2026 |
www.milliman.com |
| Phase III clinical trial data of biopharma companies in 2026 | BioWorld |
bioworld.com |
2 |
Jan 12, 2026 |
www.bioworld.com |
| FDA Accepts sNDA and Grants Priority Review to AQNEURSA® for Ataxia-Telangiectasia |
vertexaisearch.cloud.google.com |
1 |
May 19, 2026 |
www.businesswire.com |
| ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 |
vertexaisearch.cloud.google.com |
1 |
May 20, 2026 |
immunitybio.com |
| Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update |
vertexaisearch.cloud.google.com |
1 |
May 12, 2026 |
www.capricor.com |
| Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer |
vertexaisearch.cloud.google.com |
1 |
May 12, 2026 |
www.rigel.com |
| Biotech FDA Catalyst Database | FDA Catalyst Calendar | Clinical Trial Events |
vertexaisearch.cloud.google.com |
3 |
— |
biopharmiq-fronte... |
| FDA in Flux — May 2026 Newsletter | Mintz |
vertexaisearch.cloud.google.com |
2 |
May 19, 2026 |
www.mintz.com |
| Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) |
www.biospace.com |
1 |
May 20, 2026 |
www.biospace.com |
| UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC |
www.biospace.com |
1 |
May 15, 2026 |
www.biospace.com |
| Phase 3 Clinical Trials With Primary Completion Dates in May 2026 - FDA Tracker |
fdatracker.com |
1 |
May 02, 2026 |
www.fdatracker.com |
| Prescription Drug User Fee Act (PDUFA) Reauthorization - FDA |
fda.gov |
1 |
Apr 20, 2026 |
www.fda.gov |
| ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 - BioSpace |
www.biospace.com |
1 |
May 20, 2026 |
www.biospace.com |
| BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension - Business Wire |
www.businesswire.com |
1 |
May 18, 2026 |
www.businesswire.com |
| BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency - Stock Titan |
www.stocktitan.net |
1 |
May 18, 2026 |
www.stocktitan.net |
| U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain - May 18, 2026 |
vertexaisearch.cloud.google.com |
1 |
May 18, 2026 |
newsroom.viatris.com |
| BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension - Business Wire |
vertexaisearch.cloud.google.com |
1 |
May 18, 2026 |
www.businesswire.com |
| ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 | Morningstar |
vertexaisearch.cloud.google.com |
1 |
May 20, 2026 |
www.morningstar.com |
| Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN ... |
ir.veratx.com |
1 |
— |
ir.veratx.com |
| Apellis Announces FDA Acceptance and Priority Review of the New ... |
investors.apellis.com |
1 |
— |
investors.apellis.com |
| Biotech FDA Catalyst Database | FDA Catalyst Calendar | Clinical ... |
app.bpiq.com |
1 |
— |
app.bpiq.com |
| Prescription Drug User Fee Act (PDUFA) Reauthorization - FDA |
fda.gov |
1 |
Apr 20, 2026 |
www.fda.gov |
| FDA-TRACK: Prescription Drug User Fee Act (PDUFA) Performance Dashboards |
fda.gov |
1 |
Apr 17, 2026 |
www.fda.gov |
| FDA-TRACK: Prescription Drug User Fee Act (PDUFA) Performance Reports |
fda.gov |
1 |
Apr 17, 2026 |
www.fda.gov |
| Upcoming FDA Approvals: New Drugs and Therapies That May Be Approved in 2026 |
goodrx.com |
1 |
Apr 13, 2026 |
www.goodrx.com |
| This Week at FDA: FDA's leadership churn continues, PDUFA negotiations wrap up, and more | RAPS |
vertexaisearch.cloud.google.com |
2 |
May 21, 2026 |
www.raps.org |
| All Clinical Trials & Medical Discoveries News and Press Releases from PR Newswire |
vertexaisearch.cloud.google.com |
3 |
May 25, 2026 |
www.prnewswire.com |
| AstraZeneca Unveils Phase III Cancer, Rare Disease Data | Mirage News |
vertexaisearch.cloud.google.com |
1 |
May 22, 2026 |
www.miragenews.com |
| Priovant Announces FDA Acceptance and Priority Review of New ... |
investor.roivant.com |
2 |
— |
investor.roivant.com |
| FDA Increasingly Approves Drugs Based on Single Pivotal Trials, Weighing Unmet Needs and Long-Term Safety - GeneOnline |
geneonline.news |
1 |
May 22, 2026 |
www.geneonline.com |
| FDA Announces New Real-Time Clinical Trial Initiative to Expedite Development, but at What Cost? |
raps.org |
1 |
May 04, 2026 |
www.thefdalawblog.com |
| Phase 3 Clinical Trials With Primary Completion Dates in June 2025 |
www.fdatracker.com |
2 |
— |
www.fdatracker.com |
| [PDF] PDUFA REAUTHORIZATION PERFORMANCE GOALS AND ... - FDA |
www.fda.gov |
1 |
— |
www.fda.gov |
| FDA Drug Approval Decisions Expected in April 2026 - MPR - EMPR |
www.empr.com |
1 |
— |
www.empr.com |
| ImmunityBio Announces Resubmission of Supplemental BLA to the ... |
immunitybio.com |
1 |
— |
immunitybio.com |
| Rocket Pharmaceuticals Announces FDA Acceptance of BLA ... |
ir.rocketpharma.com |
1 |
— |
ir.rocketpharma.com |
| ASCO26: 5 data snapshots ahead of the year's biggest cancer drug meeting |
biopharmadive.com |
1 |
May 22, 2026 |
www.biopharmadive.com |
| Summit Therapeutics Announces U.S. FDA Acceptance of Biologics ... |
www.businesswire.com |
1 |
— |
www.businesswire.com |
| Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to Treat Primary Biliary Cholangitis (PBC) Granted Priority Review by the US FDA |
www.prnewswire.com |
1 |
May 28, 2026 |
www.prnewswire.com |
| US FDA extends PDUFA date and seeks additional data from AstraZeneca's NDA for camizestrant in combo with a CDK 4/6 inhibitor to treat HR-positive, HER2-negative advanced breast cancer |
www.pharmabiz.com |
1 |
May 28, 2026 |
www.pharmabiz.com |
| Pharma News - National Ataxia Foundation |
www.ataxia.org |
1 |
— |
www.ataxia.org |
| FDA Monthly Preview: Key June Decisions to Watch - Conexiant |
vertexaisearch.cloud.google.com |
3 |
May 29, 2026 |
conexiant.com |
| Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met ... |
ir.genmab.com |
2 |
— |
ir.genmab.com |